Indiapolis – Lilly is committed to meeting the needs of people affected by diabetes and obesity with treatment options that change the way healthcare providers can treat these diseases and offer breakthroughs for patients. The development and approvals of Mounjaro and Zepbound demonstrate our continued commitment to this mission. Patient safety is Lilly’s top priority, and we actively engage in …